Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
23 avr. 2024 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today shared details of...
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting
23 avr. 2024 08h09 HE
|
Sania Therapeutics
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting Abstracts outline an approach which is highly translatable,...
Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT
23 avr. 2024 08h00 HE
|
Tome Biosciences
Tome to present data at ASGCT.
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
23 avr. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
22 avr. 2024 16h31 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting
11 avr. 2024 07h00 HE
|
Sania Therapeutics
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on...
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
09 avr. 2024 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the...
Coave Therapeutics to Present at Upcoming Conferences
27 mars 2024 07h00 HE
|
Coave Therapeutics
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
18 mai 2023 08h00 HE
|
Outpace Bio
Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced it will...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
16 mai 2023 06h00 HE
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...